Clinical Trial Detail

NCT ID NCT02906332
Title Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hackensack University Medical Center
Indications

multiple myeloma

Therapies

Pembrolizumab

Dexamethasone

Age Groups: adult senior

No variant requirements are available.